switching from tirzepatide to retatrutide retatrutide: the complete transition guide switching from retatrutide to tirzepatide

Protocols may advise withholding long-acting GLP-1 agents 3 to 7 days prior to high-risk general anesthesia, with glucose monitoring and insulin protocols in place

One incident involving a ventilator malfunction near an MRI became known to Zoll on June 20, 2024, but FDA received the MDR, 1220908202500947, for the corresponding incident on March 10, 2025, which is beyond the 30calendar day timeframe

Mioduchoski, FNP-BC, most conversations about BPC-157 today focus not only on recovery support, but also on safety, dosing, realistic expectations, and medical supervision

Y.MaurerJ

The potential downsides of peptide therapy include side effects like fatigue, joint stiffness, or water retention if dosing isnt customized properly